Olmesartan medoxomil

Producers shown on SFDA

(Record date:02/09/2021）

Producers shown on EP

(Quoted from EP website；record date:02/09/2021）

Producer:Shanghai Sine Promod Pharmaceutical Co., Ltd.is a modern high-tech joint-stock pharmaceutical enterprise integrating scientific research, production, operation and investment. The company has five workshops: Traditional Chinese medicine extraction workshop, tablet and capsule workshop, two chemical synthesis workshops (budesonide, moclobemide), antibiotic workshop (cephalosporins), modern high-tech drug production equipment, large warehouse and R & D, inspection and experimental facilities. The five workshops have passed the GMP certification (the traditional Chinese medicine extraction workshop took the lead in passing the GMP certification in Shanghai), with an annual production capacity of 1 billion tablets and an annual output of 400 million Ginkgo biloba 

Staff size:100-199 persons

Registered capital:RMB 50 million

Producer:Beijing Wansheng Pharmaceutical Co., Ltd. is a holding subsidiary of NHU holding Investment Group Co., Ltd. and has been renamed Beijing Fuyuan Pharmaceutical Co., Ltd.

Covering an area of 27000 square meters, the company has established a production base of API, tablet and capsule that meets the requirements of GMP, with an annual production capacity of 600 million tablets, 100 million capsules and 30 tons of API.

Registered capital:RMB 360 million

Producer:Shenzhen Salubris Pharmaceuticals Co., Ltd., established in 1998 and listed on Shenzhen Stock Exchange in 2009, is a comprehensive pharmaceutical listed company integrating pharmaceutical product R & D, production and sales. The company accurately distributes the global industrial chain, covering more than 30 countries and regions such as China, the United States, Germany, France and Japan. All products and production workshops of the company have passed the domestic GMP certification, Daya Bay production base has passed the EU GMP certification, and the key product Taijia has obtained the listing license of 12 EU countries. All kinds of products enjoy a good reputation in the industry.
Staff size:About 3500 persons

Registered capital:RMB 1 billion 115 million

Producer:Yichang HEC ChangJiang Pharmaceutical Co., Ltd., formerly Yichang Changjiang Pharmaceutical Co., Ltd., was restructured into a joint stock limited company in 2015,

HEC pharmaceutical is the largest manufacturer of macrolide in the world and has passed the FDA certification; It is the largest Tamiflu production base in China; It is one of the enterprises with the highest level of producing insulin biological drugs; It is the most powerful enterprise in R & D, overseas registration and production of generic drugs in Europe, America and other developed countries; It is the first domestic pharmaceutical enterprise with independent research and development, independent registration and certification by FDA, EU and who.

Staff size:About 5000 persons

Registered capital:RM 45.202285 million

Producer:Fujian Tianquan Pharmaceutical Co., Ltd., founded in 1996, covers a total area of 38000 square meters,

Now it has many production lines of different dosage forms, such as large volume injection, small volume injection, raw material synthesis, important extraction, tablets, capsules, granules, dropping pills, soft capsules and so on.

In 2000, the first peer in the province passed the national GMP certification and the international ISO9001 and 14001 quality and environmental management system certification, and has the right of self import and export.

Registered capital:RMB 67 million 560 thousand

Producer:Zhejiang Tianyu Pharmaceutical Co., Ltd., founded in 2003, is headquartered in Taizhou, Zhejiang, with a registered capital of more than 180 million yuan. It has six wholly-owned subsidiaries and more than 3800 employees. Tianyu Co., Ltd. is a joint-stock pharmaceutical enterprise specializing in R & D, manufacturing and sales of APIs and advanced pharmaceutical intermediates. It was successfully listed on Shenzhen Stock Exchange on September 19, 2017.

The company's main products include antihypertensive, hypoglycemic, antithrombotic and antiasthmatic drug raw materials and intermediates. It is one of the world's major manufacturers of cardiovascular raw materials, and its products sell well in markets at home and abroad.

Staff size:About 4000 persons

Registered capital:RMB 348 million

Producer:Lianyungang Runzhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary and API production base of Zhengda Tianqing Pharmaceutical Group, was established in 2010, covering an area of 206 mu. In 2012, it was recognized as a high-tech enterprise, mainly engaged in the R & D, production and sales of various chemical APIs.

At present, the company has 7 product production workshops, 4 pilot workshops for new products, 1 product development center, and 2 drug inspection centers, power workshops and warehouses. There are 52 products approved for listing in China, of which 16 are listed as high-tech products in Jiangsu Province, involving liver disease, tumor, cardiovascular, respiratory and other fields, with an annual production capacity of more than 100 tons.

With the continuous increase of product types and production scale, the economic benefits of the company have also increased year by year. In 2020, the sales revenue will reach 3.5 billion yuan, including 10 API products such as arotinib hydrochloride, magnesium isoglycyrrhizinate and Diammonium Glycyrrhizinate, forming a "product group with sales of more than 100 million". The company has passed FDA certification for "zero defect" twice, and 14 products passed GMP on-site inspection in 2020, indicating that the company's quality management is at a high level in the industry.

Staff size:1000-1999 persons

Registered capital:RMB 103 million 528 thousand and 805